New 'Go-Slow' drug combo aims to help frailest myeloma patients
NCT ID NCT06517017
First seen Nov 01, 2025
Summary
This phase 2 trial tests a gradual, three-drug combination (isatuximab, dexamethasone, and lenalidomide) in 40 ultra-frail patients newly diagnosed with multiple myeloma. The goal is to see if starting treatment slowly improves how well patients tolerate therapy and their quality of life, since these patients are often too fragile for standard regimens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at the University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab, dexamethasone, and lenalidomide
What this could lead to
If successful, this could offer a more tolerable treatment option for ultra-frail multiple myeloma patients, potentially improving their quality of life and ability to stay on therapy.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The go-slow approach might not control the cancer as effectively as standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.